Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients

Objective: To evaluate the efficacy and safety of the foscarnet-ganciclovir combination in induction therapy (IT) and maintenance therapy (MT) for cyt omegalovirus (CMV) central neurological disorders in HIV-infected patients. Design: An open pilot non-comparative multicentre study. Methods: Thirty-one patients with acute CMV encephalitis (CMVe) (n = 17) or CMV myelitis (CMVm) (n =14) during the era before highly active antiretrov iral therapy (HAART) received intravenous IT with foscarnet 90 mg/kg plus g anciclovir 5 mg/kg twice a day followed by MT. The primary endpoint was cli nical efficacy, assessed at the end of the induction phase. Results: The foscarnet-ganciclovir combination in IT resulted in a 74% (23 out of 31 patients) clinical improvement or stabilization. Eight patients d id not respond clinically. Side-effects leading to drug discontinuation occ urred in 10 patients during IT. Among the 23 patients who qualified for the maintenance phase, CMV disease progressed in 10, with a median rime to the first relapse of 126 days (range 64-264 days). Overall, the median surviva l time was 3 months [95% confidence interval (CI), 2-4 months]. Conclusion: The combination of foscarnet and ganciclovir can safely be used for CMV central nervous system (CNS) infection, with an improvement or sta bilization in 74% of patients. Life-long MT with this combination is recomm ended as long as the immune system is profoundly impaired. (C) 2000 Lippinc ott Williams & Wilkins.